ArticleArchivum immunologiae et therapiae experimentalis2016

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.

Aleksandra Butrym et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.